NRx: Safety board finds no concerns with bipolar candidate

 

• The Independent Data Safety Monitoring Board identified no safety concerns and issued a recommendation to continue trial enrollment.
• No treatment-related Serious Adverse Events with first 50 enrolled clinical trial participants

https://www.biospace.com/article/releases/nrx-pharmaceuticals-reports-recommendations-of-data-safety-monitoring-board-for-trial-of-nrx-101-in-patients-with-severe-bipolar-depression-and-subacute-suicidal-ideation-or-behavior/